Conflict of interest: A. Bourdin reports grants from AstraZeneca and Boehringer Ingelheim, consulting fees from AstraZeneca, GSK, Novartis, Sanofi Regeneron, Boehringer Ingelheim, Amgen, AB Science and Med in Cell, lecture honoraria and travel support from AstraZeneca, GSK, Novartis, Sanofi Regeneron, Boehringer Ingelheim and Amgen, and advisory board participation with AstraZeneca, GSK, Novartis, Sanofi Regeneron, Boehringer Ingelheim, Amgen and AB Science, outside the submitted work. J. Charriot reports consulting fees and lecture honoraria from AstraZeneca, GSK, Novartis and Sanofi Regeneron, outside the submitted work. E. Ahmed reports consulting fees from AstraZeneca, GSK, Novartis and Sanofi Regeneron, outside the submitted work.